Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 24INDUSTRY 4OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 9Breast 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4CNS 4Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1

Conditions

Ovarian Neoplasms 4Carcinoma, Ovarian Epithelial 3Recurrence 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Standard of Care × Gynecologic × Clear all
NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT02107937 2022-05-04

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Completed
136 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02107950 2018-08-15

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Completed
71 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02107378 2016-11-30

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Terminated
22 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡